EU CHMP positive opinion for AZ's thyroid cancer drug
This article was originally published in Scrip
Executive Summary
AstraZeneca is well on its way towards EU approval of its treatment for a rare form thyroid cancer, Caprelsa (vandetanib), having received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP).